SHEET 1 of 3

FORM PTO 1449 (*modified*)	ATTY DOCKET NO. 066683/0190	SERIAL NO. 09/679,147
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	APPLICANT Tomoki Todo	
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)	FILING DATE October 5, 2000	GROUP 1614
Date Submitted to PTO: March 13, 2001		

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/OR ABSTRACT

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Publisher and location, Etc.)

DMC	A1	M. Albert, *et al.*	"Dendritic cells acquire antigen from apoptotic cells and induce class 1-restricted CTLs", The Rocekfeller University, New York, NY, *Letters to Nature*, 392: 86-89 (1998)
	A2	S. Baskar, *et al.*	"Rejection of MHC Class II-Transfected Tumor Cells Requires Induction of Tumor-Encoded B7-1 and/or B7-2 Costimulatory Molecules", The American Association of Immunologists, Bethesda, MD, *The Journal of Immunology*, 156: 3821-3827 (1996)
	A3	F. Cavallo, *et al.*	"Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response", VCH Publishers, Inc. Deerfield Beach, FL, *European Journal of Immunology*, 25: 1154-1162 (1995)
	A4	P. Chaux, *et al.*	"Inflammatory Cells Infiltrating Human Colorectal Carcinomas Express HLA Class II but Not B7-1 and B7-2 Costimulatory Molecules of the T-Cell Activation", United States and Canadian Academy of Pathology, Inc., USA, *Laboratory Investigation*, 74: 975-983 (1996)
	A5	L. Chen, *et al.*	"Tumor Immunogenicity Determines the Effect of B7 Costimulation on T Cell-mediated Tumor Immunity", The Rockefeller University Press, New York, NY, *Journal of Experimental Medicine*, 179: 523-532 (1994)
	A6	R. Denfeld, *et al.*	"*In Situ* Expression of B7 and CD28 Receptor Families in Human Malignant Melanoma: Relevance for T-Cell-Mediated Anti-Tumor Immunity", Wiley-Liss, Inc., New York, NY, *International Journal of Cancer*, 62: 259-265 (1995)
	A7	F. Falkner, *et al.*	"*Escherichia coli gpt* Gene Provides Dominant Selection for Vaccina Virus Open Reading Frame Expression Vectors", American Society for Microbiology, Washington, DC, *Journal of Virology*, 62: 1849-1854 (1988)

EXAMINER	DMC	DATE CONSIDERED	12/14/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 2 of 3

FORM PTO 1449 (*modified*) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: March 13, 2001	ATTY DOCKET NO. 066683/0190	SERIAL NO. 09/679,147
	APPLICANT Tomoki Todo	
	FILING DATE October 5, 2000	GROUP 1614

OIPE MAR 13 2001 PATENT & TRADEMARK OFFICE JC39

RECEIVED MAR 14 2001 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/OR ABSTRACT

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Publisher and location, Etc.)

DMC	A8	F. Falkner, *et al.*	"Transient Dominant Selection of Recombinant Vaccina Viruses", American Society for Microbiology, Washington, DC, *Journal of Virology*, 64: 3108-3111 (1990)
	A9	J. Galea-Lauri, *et al.*	"Novel costimulators in the immune gene therapy of cancer", Nature Publishing Group, New York, NY, *Cancer Gene Therapy*, 3: 202-214 (1996)
	A10	J. Heuer, *et al.*	"Retrovirus-Mediated Gene Transfer of B7-1 and MHC Class II Converts a Poorly Immunogenic Neurblastoma into a Highly Immunogenic One", Mary Ann Liebert, Inc., Larchmont, NY, *Human Gene Therapy*, 7: 2059-2068 (1996)
	A11	A. Huang, *et al.*	"Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens", American Association for the Advancement of Science, Washington, DC, *Science*, 264: 961-965 (1994)
	A12	E. Katsanis, *et al.*	"Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-gamma reduces their capacity to induce systemic immunity", Nature Publishing Group, New York, NY, *Cancer Gene Therapy* 3: 75-82 (1996)
	A13	E. Katsanis, *et al.*	"B7-1 Expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules", Nature Publishing Group, New York, NY, *Cancer Gene Therapy*, 2: 39-46 (1995)
	A14	Y. Li, *et al.*	"Costimulation by CD48 and B7-1 Induces Immunity against Poorly Immunogenic Tumors", The Rockefeller University Press, New York, NY, *Journal of Experimental Medicine*, 183: 639-644 (1996)
✓	A15	S. Miyatake, *et al.*	"Defective herpes simlex virus vectors expressing thymidine kinase for the treatment of malignant glioma", Nature Publishing Group, New York, NY, *Cancer Gene Therapy*, 4: 222-228 (1997)

EXAMINER DMC	DATE CONSIDERED 12/19/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 3 of 3

FORM PTO 1449 (*modified*) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: March 13, 2001	ATTY DOCKET NO. 066683/0190	SERIAL NO. 09/679,147
	APPLICANT Tomoki Todo	
	FILING DATE October 5, 2000	GROUP 1614

OIPE MAR 13 2001 PATENT & TRADEMARK OFFICE

RECEIVED MAR 14 2001 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/OR ABSTRACT

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Publisher and location, Etc.)

	A16	P. Mroz, *et al.*	"Retrovirally Transduced *Escherichia coli gpt* Genes Combine Selectability with Chemosensitivity Capable of Mediating Tumor Eradication", Mary Ann Liebert, Inc., Larchmont, NY, *Cancer Gene Therapy*, 4: 589-595 (1993)
	A17	D. Mueller, *et al.*	"Clonal Expansion Versus Functional Clonal Inactivation: A Costimulatory Signalling Pathway Determines the Outcome of T Cell Antigen Receptor Occupancy", Annual Reviews, Inc., Palo Alto, CA, *Annual Review of Immunology*, 7: 445-480 (1989)
	A18	I. Parney, *et al.*	"Granulocyte-Macrophage Colony-Stimulating Factor and B7-2 Combination Immunogene Therapy in an Allogeneic Hu-PBL-SCID/Beige Mouse-Human Glioblastoma Multiforme Model", Mary Ann Liebert, Inc., Larchmont, NY, *Human Gene Therapy*, 8: 1073-1085 (1997)
	A19	J. Rao, *et al.*	"IL-12 Is an Effective Adjuvant to Recombinant Vaccina Virus-Based Tumor Vaccines", The American Association of Immunologists, Bethesda, MD, *The Journal of Immunology*, 156: 3357-3365 (1996)
	A20	R. Schwartz, *et al.*	"*T* Cell Anergy", Scientific American, Inc., New York, NY, *Scientific American*, 62-71 (1993)
	A21	M. Toda, *et al.*	"In Situ Cancer Vaccination: An IL-12 Defective Vector/Replication-Competent Herpes Simplex Virus Combination Induces Local and Systemic Antitumor Activity", The American Association of Immunologists, Bethesda, MD, *The Journal of Immunology*, 160: 4457-4464 (1996)
	A22	L. Zitvogel, *et al.*	"Interlukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors", VCH Verlagsgesellschaft mbH, Weinheim, Germany, *European Journal of Immunology*, 26: 1335-1341 (1996)

EXAMINER	DATE CONSIDERED 12/14/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 1 of 1

FORM PTO 1449 (*modified*)	ATTY DOCKET NO.	SERIAL NO.
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	066683/0190	09/679,147
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)	APPLICANT Tomoki Todo	
Date Submitted to PTO: March 13,2001	FILING DATE October 5, 2000	GROUP 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/OR ABSTRACT

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

AMC	B1	WJR Hirst, *et al.*	"Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1", Stockton Press, Basingstoke, UK, *Gene Therapy*, 4: 691-699 (1997)
	B2	W. Marti, *et al.*	"Nonreplicating Recombinant Vaccina Virus Encoding Human B-7 Molecules Elicits Effective Costimulation of Naïve and Memory CD4+T Lyumphocytes *in Vitro*", Academic Press, San Diego, CA, *Cellular Immunology*, 179: 146-152 (1997).
	B3	K. Sturmhoefel, *et al.*	"Potent Activity of Soluble B7-IgG Fusion Porteins in Therapy of Established Tumors and as Vaccine Adjuvant", American Association for Cancer Research, Philadelphia, PA, *Cancer Research*, 59: 4964-4972 (1999)
	B4	H. Swiniarski, *et al.*	"Immune Response Ehancement by *in Vivo* Administration of B7.21g, a Soluble Costimulatory Protein", Academic Press, San Diego, CA, *Clinical Immunology*, 92: 235-245 (1999)
	B5	M. Moro, *et al.*	"Induction of Therapeutic T-Cell Immunity by Tumor Targeting with Soluble Recombinant B7-Immunoglobulin Costimulatory Molecules", American Association for Cancer Research, Philadelphia, PA, *Cancer Research*, 59: 2650-2656 (1999)
	B6	P. Challita-Eid, *et al.*	"A B7.1-Antibody Fusion Protein Retains Antibody Specificity and Ability to Activate Via the T Cell Costimulatory Pathway", The American Association of Immunologists, Bethesda, MD, *Journal of Immunology*, 160: 3419-3426 (1998)
	B7	R. Cristiano, *et al.*	"Targeted Non-Viral Gene Delivery for Cancer Gene Therapy", Frontiers in Bioscience, Manhasset, NY, *Frontiers in BioScience*, 3: 1161-1170 (1998)

EXAMINER		DATE CONSIDERED	12/14/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.